The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease

T Shirai, RR Nazarewicz, BB Wallis… - Journal of Experimental …, 2016 - rupress.org
T Shirai, RR Nazarewicz, BB Wallis, RE Yanes, R Watanabe, M Hilhorst, L Tian
Journal of Experimental Medicine, 2016rupress.org
Abnormal glucose metabolism and enhanced oxidative stress accelerate cardiovascular
disease, a chronic inflammatory condition causing high morbidity and mortality. Here, we
report that in monocytes and macrophages of patients with atherosclerotic coronary artery
disease (CAD), overutilization of glucose promotes excessive and prolonged production of
the cytokines IL-6 and IL-1β, driving systemic and tissue inflammation. In patient-derived
monocytes and macrophages, increased glucose uptake and glycolytic flux fuel the …
Abnormal glucose metabolism and enhanced oxidative stress accelerate cardiovascular disease, a chronic inflammatory condition causing high morbidity and mortality. Here, we report that in monocytes and macrophages of patients with atherosclerotic coronary artery disease (CAD), overutilization of glucose promotes excessive and prolonged production of the cytokines IL-6 and IL-1β, driving systemic and tissue inflammation. In patient-derived monocytes and macrophages, increased glucose uptake and glycolytic flux fuel the generation of mitochondrial reactive oxygen species, which in turn promote dimerization of the glycolytic enzyme pyruvate kinase M2 (PKM2) and enable its nuclear translocation. Nuclear PKM2 functions as a protein kinase that phosphorylates the transcription factor STAT3, thus boosting IL-6 and IL-1β production. Reducing glycolysis, scavenging superoxide and enforcing PKM2 tetramerization correct the proinflammatory phenotype of CAD macrophages. In essence, PKM2 serves a previously unidentified role as a molecular integrator of metabolic dysfunction, oxidative stress and tissue inflammation and represents a novel therapeutic target in cardiovascular disease.
rupress.org